<h1>Datar Cancer Genetics Unveils Target-MRD Blood Test for Early Cancer Relapse Detection in Solid Organ Cancers.</h1> Datar Cancer Genetics has launched Target-MRD, an advanced blood test for monitoring residual disease in solid organ cancers. This test combines tumor-agnostic next-generation sequencing and tumor-informed droplet digital PCR to detect minimal residual disease with high sensitivity. Target-MRD aims to identify circulating tumor-related mutations that may lead to cancer relapse, offering oncologists a tool for early intervention. It represents a significant advancement in personalized cancer care, enhancing the ability to tailor treatments and improve patient outcomes. Datar Cancer Genetics is a global leader in non-invasive cancer detection and management technologies.